Page 34 - Read Online

Page 349 Gonzalez Castillo et al. J Transl Genet Genom. 2025;9:338-51 https://dx.doi.org/10.20517/jtgg.2025.57

13. Oudet C, Hanauer A, Clemens P, Caskey T, Mandel JL. Two hot spots of recombination in the DMD gene correlate with the deletion
prone regions. Hum Mol Genet. 1992;1:599-603. DOI PubMed
14. Bez Batti Angulski A, Hosny N, Cohen H, et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front
Physiol. 2023;14:1183101. DOI PubMed PMC
15. Ricci G, Bello L, Torri F, Schirinzi E, Pegoraro E, Siciliano G. Therapeutic opportunities and clinical outcome measures in Duchenne
muscular dystrophy. Neurol Sci. 2022;43:625-33. DOI PubMed PMC
16. Tyler KL. Origins and early descriptions of "Duchenne muscular dystrophy". Muscle Nerve. 2003;28:402-22. DOI PubMed
17. Fortunato F, Rossi R, Falzarano MS, Ferlini A. Innovative therapeutic approaches for Duchenne muscular dystrophy. J Clin Med.
2021;10:820. DOI PubMed PMC
18. Szabo SM, Salhany RM, Deighton A, Harwood M, Mah J, Gooch KL. The clinical course of Duchenne muscular dystrophy in the
corticosteroid treatment era: a systematic literature review. Orphanet J Rare Dis. 2021;16:237. DOI PubMed PMC
19. Ji C, Kariyawasam DS, Sampaio H, Lorentzos M, Jones KJ, Farrar MA. Newborn screening for Duchenne muscular dystrophy: the
perspectives of stakeholders. Lancet Reg Health West Pac. 2024;45:101049. DOI PubMed PMC
20. Tavakoli NP, Gruber D, Armstrong N, et al. Newborn screening for Duchenne muscular dystrophy: a two-year pilot study. Ann Clin
Transl Neurol. 2023;10:1383-96. DOI PubMed PMC
21. Park S, Maloney B, Caggana M, Tavakoli NP. Creatine kinase-MM concentration in dried blood spots from newborns and implications
for newborn screening for Duchenne muscular dystrophy. Muscle Nerve. 2022;65:652-8. DOI PubMed PMC
22. Chien YH, Lee NC, Weng WC, et al. Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in
Taiwan. Neurol Sci. 2022;43:4563-6. DOI PubMed PMC
23. Jia C, Zhao D, Li Y, et al. Newborn screening and genomic analysis of duchenne muscular dystrophy in Henan, China. Clin Chim
Acta. 2023;539:90-6. DOI
24. Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years
experience in Wales (UK). Eur J Hum Genet. 2013;21:1049-53. DOI PubMed PMC
25. Parent Project Muscular Dystrophy. Available from https://www.parentprojectmd.org/advocacy/newborn-screening-action-center/
[Last accessed on 27 Nov 2025].
26. Chen L, Luo X, Wang H, Tian Y, Liu Y. Identifying inversions with breakpoints in the Dystrophin gene through long-read sequencing:
report of two cases. BMC Med Genomics. 2024;17:227. DOI PubMed PMC
27. Olivucci G, Iovino E, Innella G, Turchetti D, Pippucci T, Magini P. Long read sequencing on its way to the routine diagnostics of
genetic diseases. Front Genet. 2024;15:1374860. DOI PubMed PMC
28. Owusu R, Savarese M. Long-read sequencing improves diagnostic rate in neuromuscular disorders. Acta Myol. 2023;42:123-8. DOI
PubMed PMC
29. Ling C, Dai Y, Geng C, et al. Uncovering the true features of dystrophin gene rearrangement and improving the molecular diagnosis of
Duchenne and Becker muscular dystrophies. iScience. 2023;26:108365. DOI PubMed PMC
30. Wells DJ. What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy? J Muscle Res
Cell Motil. 2019;40:141-50. DOI
31. Chen G, Wei T, Yang H, Li G, Li H. CRISPR-based therapeutic gene editing for duchenne muscular dystrophy: advances, challenges
and perspectives. Cells. 2022;11:2964. DOI PubMed PMC
32. Eslahi A, Alizadeh F, Avan A, et al. New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy. Gene.
2023;867:147358. DOI
33. Chemello F, Olson EN, Bassel-Duby R. CRISPR-editing therapy for duchenne muscular dystrophy. Hum Gene Ther. 2023;34:379-87.
DOI PubMed PMC
34. Godfrey C, Muses S, McClorey G, et al. How much dystrophin is enough: the physiological consequences of different levels of
dystrophin in the mdx mouse. Hum Mol Genet. 2015;24:4225-37. DOI PubMed PMC
35. Heslop E, Turner C, Irvin A, Muntoni F, Straub V, Guglieri M; workshop participants. Gene therapy in Duchenne muscular dystrophy:
identifying and preparing for the challenges ahead. Neuromuscul Disord. 2021;31:69-78. DOI PubMed PMC
36. Roberts TC, Wood MJA, Davies KE. Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discov. 2023;22:917-
34. DOI PubMed
37. Chen SK, Hawley ZCE, Zavodszky MI, et al. Efficacy and safety of a SOD1-targeting artificial miRNA delivered by AAV9 in mice
are impacted by miRNA scaffold selection. Mol Ther Nucleic Acids. 2023;34:102057. DOI PubMed PMC
38. Xie YL, Wang JY, He Y, et al. The use of melittin to enhance transgene expression mediated by recombinant adeno-associated virus
serotype 2 vectors both in vitro and in vivo. J Integr Med. 2023;21:106-15. DOI
39. Mendell JR, Muntoni F, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3
randomized trial. Nat Med. 2025;31:332-41. DOI PubMed PMC
40. Oskoui M, Caller TA, Parsons JA, et al. Delandistrogene Moxeparvovec gene therapy in individuals with duchenne muscular
dystrophy: evidence in focus: report of the AAN guidelines subcommittee. Neurology. 2025;104:e213604. DOI
41. Manini A, Abati E, Nuredini A, Corti S, Comi GP. Adeno-associated virus (AAV)-mediated gene therapy for duchenne muscular
dystrophy: the issue of transgene persistence. Front Neurol. 2021;12:814174. DOI PubMed PMC
42. Wasala NB, Yue Y, Hu B, et al. Lifelong outcomes of systemic adeno-associated virus micro-dystrophin gene therapy in a murine
duchenne muscular dystrophy model. Hum Gene Ther. 2023;34:449-58. DOI PubMed PMC